Can a wearable sensor beat fingersticks for hospital diabetes care?

NCT ID NCT06752928

Recruiting now Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using a Dexcom G7 continuous glucose monitor (CGM) instead of standard fingerstick blood sugar checks leads to better blood sugar control and fewer dangerous lows in hospitalized adults with type 1 diabetes. One hundred participants will be randomly assigned to either the CGM or fingerstick group during their hospital stay and after discharge. The goal is to see if the CGM helps keep blood sugar in a safer range.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dexcom G7 continuous glucose monitor (device)
What this could lead to: If successful, this could show that continuous glucose monitoring improves blood sugar control and reduces dangerous lows during hospital stays for people with type 1 diabetes.
What could go wrong: This is a small, early-stage study (100 participants) comparing a device to standard care, so results may not apply broadly. The device itself has known accuracy limitations and skin irritation risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES

Contacts and locations

Locations

Grady Memorial Hospital
RECRUITING

Atlanta, Georgia, 30303, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.